Market Overview

Suono Bio Announces Appointment of Lisa Ricciardi as Chief Executive Officer


Life sciences senior executive brings operational and business
development experience to Suono Bio as company prepares to enter the

, a biotechnology company focused on enabling ultra-rapid and
formulation-independent delivery of biologics and nucleic acids,
announced today the addition of Lisa Ricciardi and appointment as CEO
effective September 1.

"The addition of Lisa to the team marks an important milestone for Suono
Bio, particularly as we prepare for our entry to the clinic," said Dr.
Carl Schoellhammer, the founding CEO who will assume the position of COO
and board member. "The company is well poised to accelerate its
activities under her leadership and I am delighted to have her join the

The addition of senior leadership comes at an exciting time for Suono
Bio, which today also announced a strategic investment by Fujifilm
Corporation to help expand its pipeline of therapeutic products. Suono
Bio leverages technology developed in the laboratory of Institute
Professor Robert Langer at the Massachusetts Institute of Technology
(MIT) to facilitate rapid, local administration of therapeutics to treat
serious diseases. The company has demonstrated pre-clinical activity in
a range of diseases using a diverse set of therapeutics, including
genetic material and proteins, at clinically-relevant doses. The company
was founded by Professor Langer, Dr. Giovanni Traverso, a
gastroenterologist and biomedical engineer at Brigham and Women's
Hospital, Harvard Medical School, Amy Schulman, partner at Polaris
Partners and executive chair of Suono Bio, and Dr. Schoellhammer.

"Lisa brings a tremendous breadth of leadership experience that,
combined with Carl's thoughtful and strategic execution and start of our
relationship with Fujifilm, will expedite the company's programs to
bring novel therapies to patients suffering from diseases with high
unmet need," added Schulman.

Over her career, Ricciardi has worked for top pharmaceutical, payer, and
molecular diagnostics firms including Pfizer, Medco, and Foundation
Medicine, and Essex Woodlands VC in strategic, transactional, and
operating roles, including multiple product launches. She is currently a
Director of UDG Healthcare plc and an advisor to Humania Capital, a
Dubai-based private equity group.

"The team has executed a strategy designed to get to the clinic quickly
and efficiently and demonstrate the technology's impact," said
Ricciardi. "I am pleased to join the Suono Bio team and bring forward a
transformational program with broad clinical application."


Suono Bio is developing therapeutic products for inflammatory-mediated
diseases leveraging their ultra-rapid and formulation independent
delivery technology. Suono Bio's platform enables rapid, localized
delivery of small molecules, biologics, and nucleic acids and gene
therapies without the need for encapsulation of the therapeutic. For
more information, please visit

View Comments and Join the Discussion!